REX CRYPTO EQUITY PREMIUM INCOME ETF(CEPI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CEPI REX CRYPTO EQUITY PREMIUM INCOME ETF

Pre-Mkt 06-11 07:28:45 EDT

32.96

-0.70

-2.08%

盘前33.13

+0.17+0.52%

07:15 EDT

High34.08	Low32.90	Vol38.56K
Open34.00	D1 Closing33.66	Amplitude3.52%
Mkt Cap104.32M	Tradable Cap104.32M	Total Shares3.17M
T/O1.29M	T/O Rate1.22%	Tradable Shares3.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CEPI","market":"US","secType":"STK","nameCN":"REX CRYPTO EQUITY PREMIUM INCOME ETF","latestPrice":32.96,"timestamp":1781121600000,"preClose":33.65988,"halted":0,"volume":38559,"hourTrading":{"tag":"盘前","latestPrice":33.13,"preClose":32.96,"latestTime":"07:15 EDT","volume":27,"amount":895.259952,"timestamp":1781176504030,"change":0.17,"changeRate":0.005158,"amplitude":0.00091},"delay":0,"changeRate":-0.020792706331692216,"floatShares":3165000,"shares":3165000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.69988,"latestTime":"06-11 07:28:45 EDT","open":34,"high":34.08,"low":32.895,"amount":1287195.04632,"amplitude":0.035205,"askPrice":38,"askSize":7,"bidPrice":32.6,"bidSize":10,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781184600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":32.96,"sharesOutstanding":2715000,"nav":33.98,"aum":107546700,"dividendRate":0.449427,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":33.13,"preClose":32.96,"latestTime":"07:15 EDT","volume":27,"amount":895.259952,"timestamp":1781176504030,"change":0.17,"changeRate":0.005158,"amplitude":0.00091},"postHourTrading":{"tag":"盘后","latestPrice":32.88,"preClose":32.96,"latestTime":"19:22 EDT","volume":579,"amount":19107.0596,"timestamp":1781133729174,"change":-0.08,"changeRate":-0.002427,"amplitude":0.003641},"volumeRatio":0.6090341203689444,"impliedVol":0.1857,"impliedVolPercentile":0.344},"requestUrl":"/m/hq/s/CEPI","defaultTab":"news","newsList":[{"id":"2635444279","title":"Press Release: Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635444279","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635444279?lang=en_us&edition=fundamental","pubTime":"2026-05-13 13:00","pubTimestamp":1778648400,"startTime":"0","endTime":"0","summary":"-- Cash position of EUR105.3 million as of end March 2026, excluding. proceeds from successful reserved offering completed in April 20261. -- Program launched in April to further reduce operating expenses. -- Pfizer expected to file regulatory submissions for Lyme disease vaccine. Lyon , May 13, 2026 -- Valneva SE , a specialty vaccine company, today reported its financial results for the first quarter ended March 31, 2026, provided key corporate updates, and updated its 2026 financial guidance. The condensed consolidated interim financial results are available on the Company's website .Valneva will provide a live webcast of its first quarter 2026 results conference call beginning. -- Total revenues were EUR30.9 million, including EUR30.5 million in product. sales, compared with EUR49.2 million and EUR48.6 million, respectively,in the first quarter of 2025, mainly reflecting the planned wind-down of. different shipment phasing to the U.S. Department of Defense. the first quarter of 202","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","VALN","BK4139","BK4022","CHIM","BK4232","BK4539","CEPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629319097","title":"Press Release: Samsung Biologics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2629319097","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629319097?lang=en_us&edition=fundamental","pubTime":"2026-04-22 14:50","pubTimestamp":1776840600,"startTime":"0","endTime":"0","summary":"-- Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW. -- Performance driven by full utilization across Plants 1 through 4 and. INCHEON, South Korea, April 22, 2026 /PRNewswire/ -- Samsung Biologics , a leading contract development and manufacturing organization , reported financial results for the first quarter of fiscal year 2026.In March, Samsung Biologics completed the acquisition of its Rockville manufacturing facility in Maryland, U.S. for USD 353 million, establishing its first U.S. manufacturing presence and further strengthening client proximity and supply chain resilience in a key market. Samsung Biologics also continues to evaluate strategic investments to further diversify its manufacturing network and support clients seeking regional supply alignment amid an evolving global operating env","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","EMXC","03160","BK4555","BK4588","BK4099","CEPI","TM","BK4604","CDMO","BK4504","BK4139","IEMG","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627741409","title":"European tissue jumbo roll prices start to rise in March as input cost increases erode margins","url":"https://stock-news.laohu8.com/highlight/detail?id=2627741409","media":"Fastmarkets","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627741409?lang=en_us&edition=fundamental","pubTime":"2026-04-14 12:00","pubTimestamp":1776139200,"startTime":"0","endTime":"0","summary":"Producers are announcing price hikes of up to €100 per tonne to offset soaring input costs, with further increases expected from April. Learn more.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fastmarkets_highlight","url":"https://www.fastmarkets.com/insights/european-tissue-jumbo-roll-prices-start-to-rise-in-march-as-input-cost-increases-erode-margins/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fastmarkets.com/insights/european-tissue-jumbo-roll-prices-start-to-rise-in-march-as-input-cost-increases-erode-margins/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fastmarkets_highlight","symbols":["CEPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607773516","title":"SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family","url":"https://stock-news.laohu8.com/highlight/detail?id=2607773516","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607773516?lang=en_us&edition=fundamental","pubTime":"2026-01-29 10:10","pubTimestamp":1769652600,"startTime":"0","endTime":"0","summary":"Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family. Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology. SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine strategy centered on universal vaccines for future pandemic preparedness. SK bioscience aims to develop a universal vaccine capable of inducing broad immune responses across the entire virus family and is establishing a platform applicable to multiple related viruses and variants.","market":"other","thumbnail":"https://mma.prnewswire.com/media/2872245/Photo_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2872245/Photo_1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sk-bioscience-initiates-international-phase-12-clinical-trial-of-universal-vaccine-candidate-targeting-sarbecovirus-family-302673365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","IPD.AU","BK7509","BK4075","CEPI","UVV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0496},{"period":"1month","weight":-0.0357},{"period":"3month","weight":0.0793},{"period":"6month","weight":-0.0778},{"period":"1year","weight":-0.176},{"period":"ytd","weight":-0.021}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","nameEN":"REX CRYPTO EQUITY PREMIUM INCOME ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"REX CRYPTO EQUITY PREMIUM INCOME ETF(CEPI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest REX CRYPTO EQUITY PREMIUM INCOME ETF(CEPI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"REX CRYPTO EQUITY PREMIUM INCOME ETF,CEPI,REX CRYPTO EQUITY PREMIUM INCOME ETF股票,REX CRYPTO EQUITY PREMIUM INCOME ETF股票老虎,REX CRYPTO EQUITY PREMIUM INCOME ETF股票老虎国际,REX CRYPTO EQUITY PREMIUM INCOME ETF行情,REX CRYPTO EQUITY PREMIUM INCOME ETF股票行情,REX CRYPTO EQUITY PREMIUM INCOME ETF股价,REX CRYPTO EQUITY PREMIUM INCOME ETF股市,REX CRYPTO EQUITY PREMIUM INCOME ETF股票价格,REX CRYPTO EQUITY PREMIUM INCOME ETF股票交易,REX CRYPTO EQUITY PREMIUM INCOME ETF股票购买,REX CRYPTO EQUITY PREMIUM INCOME ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"REX CRYPTO EQUITY PREMIUM INCOME ETF(CEPI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest REX CRYPTO EQUITY PREMIUM INCOME ETF(CEPI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}